This article was originally published in The Gray Sheet
Pending VidaMed shareholder complaint that Medtronic's $326 mil., $7.91-per-share cash acquisition deal is inadequate is without merit, VidaMed says (1"The Gray Sheet," Dec. 10, 2001, p. 18). Filed Dec. 7 in the Delaware Court of Chancery, the complaint alleges that Medtronic was able to use its minority stake in the company to compel VidaMed's board to accept a less than fair acquisition price. The $7.91 per share deal represents a 40% premium to its pre-announcement close...
You may also be interested in...
American Clinical Laboratory Association President David Sundwall, MD, says he has been contacted twice recently by the White House to determine his interest in becoming the next FDA commissioner
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.